Delivery Order SPE2DB22D1202-SPE2DB25FUTQ5

Award Date 2/25/25
Potential Completion Date 2/26/25
Potential Value $5.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,050.12 firm fixed-price delivery order is for the XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medical supply item. The contract has an ultimate completion date of November 15, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,529.01, is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. The contract has a completion date of February 4, 2025 and is a firm fixed-price delivery order. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,080.56 firm fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML medical products. The contract has an ultimate completion date of January 21, 2025 and was awarded on January 17, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,256.83 firm fixed price delivery order is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of October 24, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,480.22 firm fixed-price delivery order is for the XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML product. The contract has an ultimate completion date of November 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,857.20 firm fixed-price delivery order is for the provision of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a specialty pharmaceutical product. The contract has an ultimate completion date of December 5, 2024 and was awarded on December 4, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,089.92 Firm Fixed Price Delivery Order covers the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product, with an ultimate completion date of January 21, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medical product, and has a ceiling value of $1,641.49. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of February 19, 2025. AmerisourceBergen holds a significant Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,109.85 firm fixed price delivery order is for XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has an ultimate completion date of June 11, 2024 and was awarded on June 10, 2024. This award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,052.03, is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of February 12, 2025. The contract is not designated as a set-aside. In addition to this specific...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB25FUTQ5
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,597.19 firm fixed-price delivery order is for XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has a completion date of February 26, 2025 and was awarded on February 25, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award reviewed did not have a set-aside designation, indicating open competition.

Generated 5/27/25, 9:52 AM